---
figid: PMC12062509__41392_2025_2192_Fig3_HTML
figtitle: Copper in promoting tumor
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12062509
filename: 41392_2025_2192_Fig3_HTML.jpg
figlink: /pmc/articles/PMC12062509/figure/F3/
number: F3
caption: 'Mechanisms of copper in promoting tumor. a Copper binds to MEK1/2 and PDK1,
  activating oncogenic signaling pathways. It also activates ULK1/2 or enters the
  nucleus to induce the degradation of CRIP2, promoting autophagy. Additionally, copper
  interacts with the p53 protein, leading to its degradation. Copper also inhibits
  PDE3B, promoting lipolysis, which collectively contributes to cuproplasia. b Copper
  directly binds or activates angiogenic factors such as ANG and NO and interacts
  with HIF-1 to enhance NF-κB activity, promoting the expression of angiogenic mediators.
  Disulfide bonds formed between CTR1 and VEGFR2 activate VEGFR2 signaling, facilitating
  angiogenesis. c Copper promotes the expression of LOX/LOXL and HIF-1α, synergistically
  enhancing tumor metastasis through a positive feedback mechanism. Copper also binds
  to CD147 to promote its self-association, further enhancing metastasis. d Copper
  upregulates the expression of PD-L1 in cancer cells through multiple pathways, inhibiting
  T lymphocytes and inducing exhaustion, thereby facilitating immune escape. Created
  by BioRender. Abbreviations: ULK1/2 unc-51-like autophagy activating kinases 1 and
  2, CRIP2 copper-binding protein cysteine-rich protein 2, PDE3B phosphodiesterase
  3B, ANG angiogenin, NO nitric oxide, HIF-1 hypoxia-Inducible Factor-1, CTR1 copper
  transporter 1, VEGFR vascular endothelial growth factor receptor, LOX lysyl oxidase,
  LOXL lysyl oxidase-like protein, HIF-1α hypoxia-inducible factor-1α, PD-L1 programmed
  death-ligand 1'
papertitle: The molecular mechanism and therapeutic landscape of copper and cuproptosis
  in cancer
reftext: Ziyu Guo, et al. Signal Transduct Target Ther. 2025;10(NA).
year: '2025'
doi: 10.1038/s41392-025-02192-0
journal_title: Signal Transduction and Targeted Therapy
journal_nlm_ta: Signal Transduct Target Ther
publisher_name: Nature Publishing Group
keywords: Cancer therapy | Cancer
automl_pathway: 0.9262833
figid_alias: PMC12062509__F3
figtype: Figure
redirect_from: /figures/PMC12062509__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12062509__41392_2025_2192_Fig3_HTML.html
  '@type': Dataset
  description: 'Mechanisms of copper in promoting tumor. a Copper binds to MEK1/2
    and PDK1, activating oncogenic signaling pathways. It also activates ULK1/2 or
    enters the nucleus to induce the degradation of CRIP2, promoting autophagy. Additionally,
    copper interacts with the p53 protein, leading to its degradation. Copper also
    inhibits PDE3B, promoting lipolysis, which collectively contributes to cuproplasia.
    b Copper directly binds or activates angiogenic factors such as ANG and NO and
    interacts with HIF-1 to enhance NF-κB activity, promoting the expression of angiogenic
    mediators. Disulfide bonds formed between CTR1 and VEGFR2 activate VEGFR2 signaling,
    facilitating angiogenesis. c Copper promotes the expression of LOX/LOXL and HIF-1α,
    synergistically enhancing tumor metastasis through a positive feedback mechanism.
    Copper also binds to CD147 to promote its self-association, further enhancing
    metastasis. d Copper upregulates the expression of PD-L1 in cancer cells through
    multiple pathways, inhibiting T lymphocytes and inducing exhaustion, thereby facilitating
    immune escape. Created by BioRender. Abbreviations: ULK1/2 unc-51-like autophagy
    activating kinases 1 and 2, CRIP2 copper-binding protein cysteine-rich protein
    2, PDE3B phosphodiesterase 3B, ANG angiogenin, NO nitric oxide, HIF-1 hypoxia-Inducible
    Factor-1, CTR1 copper transporter 1, VEGFR vascular endothelial growth factor
    receptor, LOX lysyl oxidase, LOXL lysyl oxidase-like protein, HIF-1α hypoxia-inducible
    factor-1α, PD-L1 programmed death-ligand 1'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - SLC31A1
  - STEAP1
  - MTG1
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - ATOX1
  - TP53
  - TP63
  - TP73
  - ATP8A2
  - NOS3
  - ENO4
  - HIF1A
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K2
  - MAP2K1
  - PDK1
  - PDPK1
  - ULK2
  - ULK1
  - MAPK3
  - MAPK1
  - KRT12
  - SECTM1
  - AKT1
  - AKT2
  - AKT3
  - OPN1MW
  - OPN1MW2
  - OPN1MW3
  - CRIP2
  - ATG5
  - ATG13
  - PDE3B
  - FGF13
  - CXCL8
  - IL1A
  - IL6
  - NFKB1
  - EGFR
  - KDR
  - IFNA1
  - IFNR
  - IFNAR2
  - LOX
  - LOXL1
  - LOXL3
  - PARP1
  - BSG
  - GSK3A
  - GSK3B
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - MMP2
  - MMP14
  - ITK
  - SLC22A3
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - APC
  - PROC
  - GTP
  - RAS
  - Cu2+
---
